↓ Skip to main content

A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis

Overview of attention for article published in American Journal of Respiratory & Critical Care Medicine, December 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
2 news outlets
blogs
1 blog
twitter
73 tweeters
facebook
6 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
138 Dimensions

Readers on

mendeley
222 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis
Published in
American Journal of Respiratory & Critical Care Medicine, December 2015
DOI 10.1164/rccm.201505-0857oc
Pubmed ID
Authors

Joel M. Dulhunty, Jason A. Roberts, Joshua S. Davis, Steven A. R. Webb, Rinaldo Bellomo, Charles Gomersall, Charudatt Shirwadkar, Glenn M. Eastwood, John Myburgh, David L. Paterson, Therese Starr, Sanjoy K. Paul, Jeffrey Lipman

Abstract

Continuous infusion of β-lactam antibiotics may improve outcomes due to time-dependent antibacterial activity compared to intermittent dosing. To evaluate the efficacy of continuous versus intermittent infusion in patients with severe sepsis. We conducted a randomized controlled trial in 25 intensive care units (ICUs). Participants commenced on piperacillin-tazobactam, ticarcillin-clavulanate or meropenem were randomized to receive the prescribed antibiotic via continuous or 30-minute intermittent infusion for the remainder of the treatment course or until ICU discharge. The primary outcome was the number of alive ICU-free days at day 28. Secondary outcomes were 90-day survival, clinical cure 14 days post antibiotic cessation, alive organ failure-free days at day 14 and duration of bacteremia. We enrolled 432 eligible participants with a median age of 64 years and an Acute Physiology and Chronic Health Evaluation II score of 20. There was no difference in ICU-free days: 18 days (IQR: 2-24) and 20 days (IQR 3-24) in the continuous and intermittent groups (P = 0.38). There was no difference in 90-day survival: 74.3% (156/210) and 72.5% (158/218); HR 0.91 (95% CI 0.63-1.31, P = 0.61). Clinical cure was 52.4% (111/212) and 49.5% (109/220); OR 1.12 (95% CI 0.77-1.63, P = 0.56). There was no difference in organ-failure free days (6 days, P = 0.27) and duration of bacteremia (0 days, P = 0.24). In critically ill patients with severe sepsis, there was no difference in outcomes between β-lactam antibiotic administration by continuous and intermittent infusion. Clinical trial registration available at www.anzctr.org.au, ID ACTRN12612000138886.

Twitter Demographics

The data shown below were collected from the profiles of 73 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 222 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 1%
Germany 2 <1%
Japan 2 <1%
Australia 1 <1%
Netherlands 1 <1%
France 1 <1%
Brazil 1 <1%
Chile 1 <1%
Ireland 1 <1%
Other 0 0%
Unknown 209 94%

Demographic breakdown

Readers by professional status Count As %
Other 39 18%
Researcher 30 14%
Student > Master 28 13%
Student > Ph. D. Student 27 12%
Student > Postgraduate 17 8%
Other 43 19%
Unknown 38 17%
Readers by discipline Count As %
Medicine and Dentistry 119 54%
Pharmacology, Toxicology and Pharmaceutical Science 23 10%
Nursing and Health Professions 8 4%
Immunology and Microbiology 4 2%
Agricultural and Biological Sciences 4 2%
Other 11 5%
Unknown 53 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 66. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 October 2018.
All research outputs
#365,030
of 16,521,405 outputs
Outputs from American Journal of Respiratory & Critical Care Medicine
#299
of 8,678 outputs
Outputs of similar age
#5,982
of 237,462 outputs
Outputs of similar age from American Journal of Respiratory & Critical Care Medicine
#7
of 135 outputs
Altmetric has tracked 16,521,405 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,678 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.0. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 237,462 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 135 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.